Chondroitin sulfate (1200
mg/day) has been shown to be
superior to celecoxib (200mg per
day) at reducing cartilage loss while
demonstrating similar efficacy at
reducing disease symptoms in
knee osteoarthritis (OA) patients,
according to a two-year doubleblind
randomised controlled
multi-centre study presented to the
American College of Rheumatology
Annual Meeting in San Francisco.
Lead author Professor Jean-
Pierre Pelletier director, Rheumatic
Disease Unit, University of
Montreal School of Medicine
cautioned that the study used
pharmaceutical-grade chondroitin
as opposed to food-supplement
chondroitin.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Nov 15
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.